Leukemia inhibitory factor gene is associated with schizophrenia and working memory function

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 172-176

  Okahisa, Yuko ^a   Ujike, Hiroshi ^a   Kunugi, Hiroshi ^b   Ishihara, Takeshi ^a   Kodama, Masafumi ^a   Takaki, Manabu ^a   Kotaka, Tatsuya ^a   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Case control association; Cognitive function; Leukemia inhibitory factor; Schizophrenia

Indexed keywords

LEUKEMIA INHIBITORY FACTOR;

ADULT; ARTICLE; CHROMOSOME 22Q; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; NUCLEOTIDE SEQUENCE; PARANOID SCHIZOPHRENIA; SCHIZOPHRENIA; WECHSLER INTELLIGENCE SCALE; WECHSLER MEMORY SCALE; WISCONSIN CARD SORTING TEST; WORKING MEMORY;

ADULT; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LEUKEMIA INHIBITORY FACTOR; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 73649134645     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.10.020     Document Type: Article

References (52)

1. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 37 (1999) 97-106
2. Badner J.A., and Gershon E.S. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7 (2002) 405-411
3. Bains J.S., and Oliet S.H. Glia: they make your memories stick!. Trends Neurosci 30 (2007) 417-424
4. Barnabe-Heider F., Wasylnka J.A., Fernandes K.J., Porsche C., Sendtner M., Kaplan D.R., et al. Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1. Neuron 48 (2005) 253-265
5. Benes F.M., Davidson J., and Bird E.D. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 43 (1986) 31-35
6. Bonni A., Sun Y., Nadal-Vicens M., Bhatt A., Frank D.A., Rozovsky I., et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278 (1997) 477-483
7. Borrell J., Vela J.M., Arevalo-Martin A., Molina-Holgado E., and Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26 (2002) 204-215
8. Brown A.S. The risk for schizophrenia from childhood and adult infections. Am J Psychiatry 165 (2008) 7-10
9. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61 (2004) 774-780
10. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br Med J 280 (1980) 66-68
11. Everett J., Lavoie K., Gagnon J.F., and Gosselin N. Performance of patients with schizophrenia on the Wisconsin Card Sorting Test (WCST). J Psychiatry Neurosci 26 (2001) 123-130
12. Faries D., Ascher-Svanum H., Zhu B., Correll C., and Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5 (2005) 26
13. Fatemi S.H., Reutiman T.J., Folsom T.D., Huang H., Oishi K., Mori S., et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 99 (2008) 56-70
14. Franke P., Maier W., Hain C., and Klingler T. Wisconsin Card Sorting Test: an indicator of vulnerability to schizophrenia?. Schizophr Res 6 (1992) 243-249
15. Gallhofer B., Jaanson P., Mirttoux A., Tanghoj P., Lis S., and Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: a randomized double-blind study comparing sertindole and haloperidole. Pharmacopsychiatry 40 (2007) 275-286
16. Gill M., Vallada H., Collier D., Sham P., Holmans P., Murray R., et al. A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (Chromosome 22). Am J Med Genet 67 (1996) 40-45
17. He F., Ge W., Martinowich K., Becker-Catania S., Coskun V., Zhu W., et al. A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis. Nat Neurosci 8 (2005) 616-625
18. Holmberg K.H., and Patterson P.H. Leukemia inhibitory factor is a key regulator of astrocytic, microglial and neuronal responses in a low-dose pilocarpine injury model. Brain Res 1075 (2006) 26-35
19. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 86 (2006) 138-146
20. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., et al. Disease-specific alternations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 5 (2000) 142-149
21. Kashima H, Handa T, Kato M, Sakura K, Yokoyama N, Murakami M, et al. Neuropsychological investigation on chronic schizophrenia-aspects of its frontal functions. In: Takahashi R, Flor-Henry P, Gruzelier J and Niwa S, (Eds.), Cerebral Dynamics, Laterality and Psychopathology, Elsevier, Amsterdam 1987, p. 337-45
22. Kerr B.J., and Patterson P.H. Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp Neurol 188 (2004) 391-407
23. Kerr B.J., and Patterson P.H. Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 51 (2005) 73-79
24. Kobayashi S. Wisconsin Card Sorting Test Program Keio-F-S-version (Web site, in Japanese) 1999. Available at:http://cvddb.shimane-med.ac.jp/user/wisconsin.htm
25. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 73 (2003) 34-48
26. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54 (2002) 281-291
27. Martino DJ., Bucay D., Butnam J.T., and Allegri RF. Neuropsychological frontal impairments and negative symptoms in schizophrenia. Psychiatry Res 59 (2007) 127-128
28. Meyer U., Feldon J., and Yee B.K. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35 (2008) 959-972
29. Nawa H., Takahashi M., and Patterson P.H. Cytokine and growth factor involvement in schizophrenia-support for the developmental model. Mol Psychiatry 5 (2000) 594-603
30. Otsubo T., Tanaka K., Koda R., Shinoda J., Sano N., Tanaka S., et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci 59 (2005) 517-526
31. Procyshyn R.M., Kennedy N.B., Tse G., and Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46 (2001) 334-339
32. Pulver A.E., Karayiorgou M., Wolyniec P.S., Lasseter V.K., Kasch L., Nestadt G., et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: part 1. Am J Med Genet 54 (1994) 36-43
33. Romero E, Guaza C, Castellano B, Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry 2008; in press. doi:10.1038/m.p.2008.44.
34. Rybakowski J.K., and Borkowska A. Eye movement and neuropsychological studies in first-degree relatives of schizophrenic patients. Schizophr Res 54 (2002) 105-110
35. Rybakowski J.K., Drozdz W., and Borkowska A. Long-term administration of the low-dose risperidone in schizotaxia subjects. Hum Psychopharmacol 22 (2007) 407-412
36. Sanfilipo M., Lafargue T., Rusinek H., Arena L., Loneragan C., Lautin A., et al. Volumetric measures of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 57 (2000) 471-480
37. Segurado R., Detera-Wadleigh S.D., Levinson D.F., Lewis C.M., Gill M., Nurnberger Jr. J.I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 73 (2003) 49-62
38. Sim K., Su A., Fujii S., Yang S.Y., Chong M.Y., Ungvari G.S., et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58 (2004) 178-183
39. Sim K., Su A., Leong J.Y., Yip K., Chong M.Y., Fujii S., et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 37 (2004) 175-179
40. Stark A.K., Uylings H.B., Sanz-Arigita E., and Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 161 (2004) 882-888
41. Steffek A.E., McCullumsmith R.E., Haroutunian V., and Meador-Woodruff J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 103 (2008) 71-82
42. Sugiura S., Lahav R., Han J., Kou S.Y., Banner L.R., de Pablo F., et al. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci 12 (2000) 457-466
43. Suhr J.A., and Spitznagel M.B. Factor versus cluster models of schizotypal traits. ΙΙ: relation to neuropsychological impairment. Schizophr Res 52 (2001) 241-250
44. Sutherland G.R., Baker E., Hyland V.J., Callen D.F., Stahl J., and Gough N.M. The gene for human leukemia inhibitory factor (LIF) maps to 22q12. Leukemia 3 (1989) 9-13
45. Taga T., and Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15 (1997) 797-819
46. Tohmi M., Tsuda N., Watanabe Y., Kakita A., and Nawa H. Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neuro Res 50 (2004) 67-75
47. Toyooka K., Watanabe Y., Iritani S., Shimizu E., Iyo M., Nakamura R., et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci Res 46 (2003) 299-307
48. Urakubo A., Jarskog L.F., Lieberman J.A., and Gilmore J.H. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res 47 (2001) 27-36
49. Watanabe Y., Hashimoto S., Kakita A., Takahashi H., Ko J., Mizuno M., et al. Neonatal impact of leukemia inhibitory factor on neurobehavioral development in rats. Neurosci Res 48 (2004) 345-353
50. Webster M.J., O'Grady J., Kleinman J.E., and Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulated cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133 (2005) 453-461
51. Weinberger D.R., Berman K.F., and Zec R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43 (1986) 114-124
52. Wolkin A., Choi S.J., Szilagyi S., Sanfilipo M., Rotrosen J.P., and Lim K.O. Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am J Psychiatry 160 (2003) 572-574